Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
11
8
2018
medline:
13
3
2020
entrez:
11
8
2018
Statut:
ppublish
Résumé
: Topiramate is a non-benzodiazepine anticonvulsant medication with multi-faceted pharmacologic action. It has emerged as an efficacious pharmacotherapeutic option for the treatment of addiction, especially alcohol use disorder (AUD). We present a broad narrative review of the putative mechanism of action and clinical utility of topiramate with regard to AUD and other substance use disorders. Collective evidence suggests topiramate is an effective treatment option in AUD, with notable efficacy in reducing harmful drinking patterns in AUD. Though not currently approved by the United States Food and Drug Administration for the indication of AUD, topiramate should be considered as a pharmacological treatment option with high utility among AUD patients. Early pharmacogenetic studies raise the intriguing possibility of identifying patients likely to respond to topiramate using genetic testing, and initial studies show that topiramate may also be useful in treating cocaine use disorder, smoking cessation and behavioral addictions. However, further research is needed in all these areas.
Identifiants
pubmed: 30096077
doi: 10.1097/ADM.0000000000000443
doi:
Substances chimiques
Neurotransmitter Agents
0
Topiramate
0H73WJJ391
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-22Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA024466
Pays : United States
Organisme : NIDA NIH HHS
ID : R25 DA033211
Pays : United States